$45.61−0.12 (−0.26%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
AnaptysBio (ANAB) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
14 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~38.8%/yr (FY21→FY25), net margin −5.6%. Worth your attention in FY25: Returns vs FCF (350%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲157.0%
234.6
FY21→FY25CAGR +38.8%/yr
Net income ($M)▲90.9%
−13.2
FY21→FY25CAGR —
Free cash flow ($M)—
19.6
FY21→FY25CAGR —
Diluted EPS▲91.0%
−0.46
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+4.8%
27.4mn → 28.8mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$87.0K
−75.7% YoY in FY25 · 0.0% of revenue.
Returns vs FCF
350%
$68.6M returned vs $19.6M of FCF in FY25. The gap comes off the balance sheet (see net cash).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-6¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -5.6% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 234,603.0 | 91,280.0 | 17,157.0 | 10,287.0 | 63,175.0 | ▲157.0% | +38.8% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | —A | —A | —A | 10,287.0 | 63,175.0 | — | — |
Research & development | — | 135,970.0 | 163,840.0 | 139,622.0 | 88,798.0 | 98,496.0 | ▼17.0% | +8.4% |
Selling, general & admin | — | 50,737.0 | 42,389.0 | 41,946.0 | 36,643.0 | 21,493.0 | ▲19.7% | +24.0% |
Total operating expenses | — | 186,707.0 | 206,229.0 | 181,568.0 | 125,441.0 | 119,989.0 | ▼9.5% | +11.7% |
Operating incomefeeds ROC rank | — | 47,896.0 | −114,949.0 | −164,411.0 | −115,154.0 | −56,814.0 | — | — |
Other income, net | — | −60,964.0 | −30,279.0 | 788.0 | −13,546.0 | −982.0 | — | — |
Pretax income | — | −13,068.0 | −145,228.0 | −163,623.0 | −128,700.0 | −57,796.0 | ▲91.0% | — |
Income tax | — | 164.0 | 3.0 | −4.0 | 24.0 | 0.0 | ▲5366.7% | +89.8% (22→25) |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | — | −13,232.0 | −145,231.0 | −163,619.0 | −128,724.0 | −57,796.0 | ▲90.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −0.46 | −5.12 | −6.08 | −4.57 | −2.11 | ▲91.0% | — |
Diluted shares (mn) | 35.07 | 28.76 | 28.38 | 26.92 | 28.16 | 27.43 | ▲1.3% | +1.2% |
| Margins | ||||||||
Gross margin | — | —A | —A | —A | 100.0% | 100.0% | — | — |
Operating margin | — | 20.4% | −125.9% | −958.3% | −1119.4% | −89.9% | ▲146.3pp | +110.3pp |
Net margin32nd pct in Healthcare | — | −5.6% | −159.1% | −953.7% | −1251.3% | −91.5% | ▲153.5pp | +85.8pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 6 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was AnaptysBio's revenue last fiscal year?
AnaptysBio reported revenue of $234.6M in fiscal 2025, up 157.0% from fiscal 2024.
What was AnaptysBio's net income?
AnaptysBio reported net income of −$13.2M in fiscal 2025, a net margin of −5.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

